Expertise in
5
conditions

Naoko Hosono

JP 
Expertise in
5
conditions
JP 

Overview

Naoko Hosono practices practicing medicine in Japan.

Ms. Hosono is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Familial Wilms Tumor 2, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 76 peer reviewed articles.

Gender

Female

Locations

Japan
Other Locations
Matsuoka, 9101193, Japan
Matsuoka, 9101193, Japan

Frequently Asked Questions about Naoko Hosono

Is Naoko Hosono a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Naoko Hosono is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Naoko Hosono participate in research or clinical trials?

Yes. Naoko Hosono has published 76 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Naoko Hosono's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hosono's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile